Drugs / UB-311
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00965588 | Feb 2009 → Apr 2011 | Alzheimer disease | United Biomedical | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03531710 | Aug 2018 → Oct 2019 | Alzheimer disease | United Neuroscience Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT02551809 | Oct 2015 → Aug 2018 | Alzheimer disease | United Neuroscience Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UB-311 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02551809 ↗ |
| Known as | UBITh AD Immunotherapeutic Vaccine | “A Phase I, Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of the UBITh AD Immunotherapeutic Vaccine (UB 311) in Patients With Mild to Moderate...” NCT00965588 ↗ |
| Modality | Vaccine | “the vaccine (UB 311), targeting the amyloid beta peptide (N-terminal amino acids, 1-14)” NCT00965588 ↗ |
| Route | Intramuscular | “Single liquid dose by intramuscular route” NCT00965588 ↗ |